Insulin analogues: Searching for a physiological replacement Análoges de insulina: En búsqueda del reemplazo fisiológico
Eyzaguirre C., Francisca
Codner Dujovne, Ethel
Cita de ítem
Revista Medica de Chile, Volumen 134, Issue 2, 2018, Pages 239-250
Insulin analogues, developed by molecular engineering, have structural changes in the A and B insulin chains. These modifications change their action profile, rendering insulin replacement closer to physiology. Rapid acting analogues like lispro, a spart and glulisine, are absorbed rapidly from the subcutaneous tissue to the circulation. In addition, two long acting insulin analogues have been developed: glargine and detemir. The combination of a long acting insulin, to maintain baseline levels, and multiple daily doses of a rapid acting analogue are the mainstay of basal-bolus therapy. Multiples studies have compared human insulin (NPH and regular) with insulin analogues in patients with type 1 or 2 diabetes mellitus, showing an improvement in the metabolic control, fewer hypoglycemic events and better quality of life. In summary, insulin analogues offer new therapeutic options and allow an individualized intensive treatment.
Oróstica Arévalo, Maria Lorena; Astorga Leiva, Isis; Plaza Parrochia, Francisca; Poblete Rivas, Cristian; Carvajal Gavilán, Rodrigo; García Angulo, Víctor; Romero Osses, Carmen; Vega Blanco, María Margarita(MDPI, 2022)
Polycystic ovary syndrome (PCOS) is an endocrine/metabolic disorder associated with insulin resistance (IR) and obesity. Endometria from women with PCOS present failures in insulin action, glucose uptake and signaling of ...
Reduced adenosine uptake via human equilibrative nucleoside transporter 1 (hENT1) in human umbilical vein endothelial cells (HUVECs) from gestational diabetes mellitus (GDM) is reversed by insulin by restoring hENT1 ...
Bazaes Castillo, Rodrigo Antonio; Petry, C. J.; Ong, Ken; Avila, Alejandra; Dunger, D. B.; Mericq, Verónica(BLACKWELL PUBLISHING, 2003-11)
AIMS We have previously demonstrated that insulin sensitivity and secretion at age 1 year was in part related to variation in weight and height gain during infancy. In order to determine whether genetic variation at the ...